Compare Regeneron Pharmaceuticals Inc (REGN) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Western Digital Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Western Digital Corp trades at $480.5 (market cap $172.09B). The key difference: Western Digital Corp is far larger — about 2.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| REGN | WDC | |
|---|---|---|
Market Cap | $83.43B | $172.09B |
Sector | Health | Technology |
52-Week High | $852.03 | $746.23 |
52-Week Low | $555.51 | $95.03 |
Enterprise Value | $78.14B | $171.56B |
Dividend Yield | 0.46% | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Western Digital (WDC) trades at $477.30, up 2.1% today, reflecting strong momentum amid AI-driven storage demand. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $676.70 suggesting 42% upside. Fundamentals are robust, with a net income margin of 71.97% in 2025 and positive cash flow trends, though revenue declined to $9.52B from prior years.
Outlook remains positive due to AI data growth catalysts and shareholder returns, but risks include competitive pressures and volatility from high expectations. The stock's valuation multiples like P/E of 17.73 appear reasonable given growth prospects, supporting a bullish bias with caution on execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
